Library

Displaying 26 - 50 of 2,688

ISLB and MCM Symposia
ISLB and MCM Symposia
By: Christian Rolfo, MD, PhD, MBA, Dr.h.c, Ticiana A. Leal, MD
Current Status of Biosimilars and Recent Approvals
Current Status of Biosimilars and Recent Approvals
By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
Biosimilars Implementation in the US: A Five Year Review
Biosimilars Implementation in the US: A Five Year Review
By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
Biosimilars as Front-Line Options for Cancer Care
Biosimilars as Front-Line Options for Cancer Care
By: Jorge J. García, PharmD, MS, MHA, MBA, FACHE
Tumor Biology, Pathology, Novel Diagnostics
Tumor Biology, Pathology, Novel Diagnostics
By: Tianhong “Tina” Li, MD, PhD
The Challenges of Biosimilars in the Daily Oncology Practice?
The Challenges of Biosimilars in the Daily Oncology Practice?
By: Dina B. Dumercy McHenry, PharmD, MBA, BCOP
Clinical Update: Biosimilars to Adalimumab
Clinical Update: Biosimilars to Adalimumab
By: Johnny Chang, PharmD, BCPS, CSP
How Far Have We Gone with Biosimilars?
How Far Have We Gone with Biosimilars?
By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
How Far Have We Gone with Biosimilars?
How Far Have We Gone with Biosimilars?
By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE